Q11 Stock Overview
Viromed Medical AG engages in the development and distribution of products in diagnostics, therapeutics, and cold plasma technology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Viromed Medical AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.36 |
| 52 Week High | €5.60 |
| 52 Week Low | €1.36 |
| Beta | 0 |
| 1 Month Change | -35.87% |
| 3 Month Change | -37.89% |
| 1 Year Change | 4.42% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 136.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| Q11 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -17.5% | 2.1% | 0.5% |
| 1Y | 4.4% | -8.4% | 1.3% |
Return vs Industry: Q11 exceeded the German Medical Equipment industry which returned -7.7% over the past year.
Return vs Market: Q11 exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| Q11 volatility | |
|---|---|
| Q11 Average Weekly Movement | 10.9% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: Q11's share price has been volatile over the past 3 months.
Volatility Over Time: Q11's weekly volatility has decreased from 18% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | n/a | www.viromed-medical-ag.de |
Viromed Medical AG engages in the development and distribution of products in diagnostics, therapeutics, and cold plasma technology. The company was formerly known as Fonterelli SPAC2 AG. Viromed Medical AG was incorporated in 2021 and is based in Pinneberg, Germany.
Viromed Medical AG Fundamentals Summary
| Q11 fundamental statistics | |
|---|---|
| Market cap | n/a |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs Q11 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| Q11 income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did Q11 perform over the long term?
See historical performance and comparison